These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29304946)

  • 21. Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
    Tian J; Luo Y; Xiang J; Tang J
    J Neurooncol; 2017 Nov; 135(2):217-227. PubMed ID: 28726172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
    Zhou F; Jiang T; Ma W; Gao G; Chen X; Zhou C
    Lung Cancer; 2015 Aug; 89(2):203-11. PubMed ID: 26115839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
    Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.
    Hotta K; Kiura K; Fujiwara Y; Takigawa N; Hisamoto A; Ichihara E; Tabata M; Tanimoto M
    PLoS One; 2011; 6(11):e26646. PubMed ID: 22114662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
    Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
    Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
    Li X; Wang H; Lin W; Xu Q
    Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Schulz C; Mansmann U; Heinemann V
    Acta Oncol; 2015 Feb; 54(2):187-93. PubMed ID: 25017379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
    Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
    Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.
    Liu LY; Yu H; Bai JL; Zeng P; Miao DD; Chen F
    Asian Pac J Cancer Prev; 2015; 16(3):1001-6. PubMed ID: 25735320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
    Hotta K; Suzuki E; Di Maio M; Chiodini P; Fujiwara Y; Takigawa N; Ichihara E; Reck M; Manegold C; Pilz L; Hisamoto-Sato A; Tabata M; Tanimoto M; Shepherd FA; Kiura K
    Lung Cancer; 2013 Jan; 79(1):20-6. PubMed ID: 23164554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 35. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
    Gao G; Chu H; Zhao L; Gui T; Xu Q; Shi J
    Lung Cancer; 2012 Jun; 76(3):380-6. PubMed ID: 22226626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
    Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
    Liu L; Cao Y; Tan A; Liao C; Gao F
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.